Literature DB >> 27318845

Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis.

George C M Siontis1, Raffaele Piccolo1, Fabien Praz1, Marco Valgimigli1, Lorenz Räber1, Dimitris Mavridis2, Peter Jüni3, Stephan Windecker4.   

Abstract

OBJECTIVES: This study evaluated the most appropriate percutaneous coronary intervention (PCI) for the treatment of stenoses in small coronary arteries.
BACKGROUND: PCI in small coronary arteries is associated with an increased risk of lesion failure and restenosis.
METHODS: Randomized trials comparing different PCI strategies were identified through a broad search of published reports. Primary angiographic outcome was %DS (%DS). A pairwise meta-analysis was performed by using random effects model, followed by a network meta-analysis synthesizing direct and indirect evidence.
RESULTS: Overall, 19 trials were eligible, which included 5,072 patients comprising a network without closed loops among 5 identified interventions (early generation sirolimus-eluting stents [SES], paclitaxel-eluting stents [PES], drug-coated balloons [DCB], bare-metal stents [BMS], and balloon angioplasty [BA]). No dedicated trial was identified evaluating new generation drug-eluting stents. Early generation SES yielded the best angiographic results according to %DS. For %DS, SES was ranked as the most effective treatment, followed by PES (standardized mean differences [SMD]: -0.44; 95% confidence interval [CI]: -0.92 to 0.05 vs. SES) and DCB (SMD: -0.89; 95% CI: -1.53 to -0.25 vs. SES). In terms of absolute differences, SES yielded a reduction of 18% in diameter stenosis compared to DCB. SES significantly reduced the risk of target-lesion revascularization compared to PES (odds ratio [OR]: 0.39; 95% CI: 0.16 to 0.93), DCB (OR: 0.34; 95% CI: 0.10 to 0.97), BMS (OR: 0.21; 95% CI: 0.13 to 0.36), and BA (OR: 0.16; 95% CI: 0.09 to 0.29).
CONCLUSIONS: Early generation SES yielded the most favorable angiographic and clinical outcomes for the treatment of stenoses in small coronary arteries. New generation DES need to be evaluated against this standard in future randomized trials.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  coronary disease; drug-coating balloon(s); drug-eluting stent(s); network meta-analysis; small coronary arteries

Mesh:

Year:  2016        PMID: 27318845     DOI: 10.1016/j.jcin.2016.03.025

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  14 in total

1.  Best percutaneous coronary intervention approach for small caliber coronary arteries.

Authors:  Amir Solomonica; Ariel Roguin
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

2.  Novel treatments for in-stent restenosis: sirolimus-eluting balloons enter the arena.

Authors:  Raffaele Piccolo; Tullio Niglio; Anna Franzone; Bruno Trimarco; Giovanni Esposito
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

Review 3.  Small vessel coronary artery disease: How small can we go with myocardial revascularization?

Authors:  Maciej T Wybraniec; Paweł Bańka; Tomasz Bochenek; Tomasz Roleder; Katarzyna Mizia-Stec
Journal:  Cardiol J       Date:  2020-09-28       Impact factor: 2.737

4.  Efficacy of Drug-Coated Balloon Approaches for de novo Coronary Artery Diseases: A Bayesian Network Meta-Analysis.

Authors:  Peng-Yu Zhong; Ying Ma; Yao-Sheng Shang; Ying Niu; Nan Bai; Zhi-Lu Wang
Journal:  Front Cardiovasc Med       Date:  2022-06-21

5.  First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study.

Authors:  Raban Jeger; Matthias Pfisterer; Otmar Pfister; Peter Rickenbacher; Michael Handke; Nicole Gilgen; Michael Coslovsky; Christoph Kaiser
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-11-17       Impact factor: 1.426

6.  Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2.

Authors:  Nicole Gilgen; Ahmed Farah; Bruno Scheller; Marc-Alexander Ohlow; Norman Mangner; Daniel Weilenmann; Jochen Wöhrle; Peiman Jamshidi; Gregor Leibundgut; Sven Möbius-Winkler; Robert Zweiker; Florian Krackhardt; Christian Butter; Leonhard Bruch; Christoph Kaiser; Andreas Hoffmann; Peter Rickenbacher; Christian Mueller; Frank-Peter Stephan; Michael Coslovsky; Raban Jeger
Journal:  Clin Cardiol       Date:  2018-05-10       Impact factor: 2.882

7.  Drug-coated balloon versus drug-eluting stent in de novo small coronary vessel disease: A systematic review and meta-analysis.

Authors:  Min Li; Chen Guo; Yong-Hui Lv; Ming-Bo Zhang; Zhi-Lu Wang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

8.  Clinical outcomes of drug-coated balloon in coronary lesions: a real-world, all-comers study.

Authors:  Liang Pan; Wenjie Lu; Zhanying Han; Sancong Pan; Xi Wang; Yingguang Shan; Xule Wang; Xiaolin Zheng; Ran Li; Yanjun Zhou; Peng Qin; Qiangwei Shi; Shuai Zhou; Wencai Zhang; Sen Guo; Peisheng Zhang; Xiaofei Qin; Guoju Sun; Zhongsheng Qin; Zhenwen Huang; Chunguang Qiu
Journal:  Clin Res Cardiol       Date:  2021-07-27       Impact factor: 5.460

9.  Hybrid rotablation and drug-eluting balloon strategy.

Authors:  Ahmed Vachiat; Mpiko Ntsekhe; Farrel Hellig
Journal:  Cardiovasc J Afr       Date:  2020-11-12       Impact factor: 1.167

10.  Comparing efficacy of drug-coated balloon-only approach and stent approach in treating de novo coronary artery lesions: A meta-analysis of randomized controlled trials. A protocol for systematic review and meta-analysis.

Authors:  Deshuai Yu; Junjun Cai; Kai Wang; Tianli Li; Leilei Liu; Lei Shi; Xian Wang
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.